PD-1/PD-L1
Clinical Development of PD-1/PD-L1 Immunotherapy for Gastrointestinal Cancers: Facts and Hopes.
... phase 1 study of cobimetinib (MEK inhibitor) with atezolizumab (PD-L1 antibody) was conducted with an expanded cohort in mCRC ...with PD-1 ...
42
Drug response to PD-1/PD-L1 blockade: based on biomarkers
... Until now, five anti-PD-1/PD-L1 drugs have received approval by the US Food and Drug Administration (FDA), including anti-PD-1 drugs such as pembrolizumab (Keytruda; Merck & ...
11
Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series
... There are numerous opportunities to address mecha- nisms of resistance to immunotherapy other than retreatment with PD-1/PD-L1 monotherapy. For ex- ample, anti-Vascular Endothelial Growth ...
5
PD-1/PD-L1 blockades in non-small-cell lung cancer therapy
... contrast, PD-1 is primarily to inhibit activated T-cell function via its interaction with PD-L1 and ...that PD-1 ligation inhibited PI3K activity and downstream AKT activation, ...
14
Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China
... When PD-1 binds to its ligands, such as programmed cell death protein ligand 1 (PD-L1) and programmed cell death protein ligand 2, T cell activity and cytokine production is greatly ...
8
Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
... cancer; PD: Progressive disease; PD-1: Programmed cell death-1; PD-L1: Programmed cell death ligand-1; PD-L2: Programmed cell death ligand-2; PFS: Progression- free ...
21
Oncolytic virus and PD-1/PD-L1 blockade combination therapy
... killer; PD-1, programmed cell death protein 1; PD-L1, programmed cell death ligand 1; SFV, Semliki Forest virus; SQ, subcutaneous; TAA, tumor-associated antigen; TK, thymidine ...
13
Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis
... of PD-1 and PD-L1 antibodies has been established in a wide spectrum of solid and hematological ...including PD-1 and PD-L1 inhibi- ...
8
Targeting PD-1/PD-L1 in lung cancer: current perspectives
... of nivolumab every 2 weeks. This trial included patients regardless of their PD-L1 status. The most common adverse reactions (reported in $20% of patients) were fatigue (50%), dyspnea (38%), musculoskeletal ...
16
Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy
... is PD-L1 expression assessed via IHC on tumor biopsies, although limitations are obviously ...of PD-1 and/or PD-L1 expression, which should enable mapping of primary tumors and ...
12
Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
... the PD-1/PD-L1 pathway has elicited durable antitumor responses in the therapy of a broad spectrum of ...cancers. PD-L1 is constitutively expressed in certain tumors and host ...
8
Contribution of NK cells to immunotherapy mediated by PD 1/PD L1 blockade
... generated PD-L1 transductants of B16 (hereafter abbreviated ...expressed PD-1 in only half of tumor-bearing animals and at a low frequency (Figure 2C), so it was not surprising that B16-Pdl1 ...
16
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
... targets PD-1, has been approved as a first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with positive PD-L1 ...However, PD-1/PD-L1 ...
13
High-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers
... both PD-1 and PD-L1 in lymph ...the PD-1 mAb tracer is particularly remarkable not only because the lymph nodes are small but also because they contain only few, small ...
12
The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy
... that PD-1/PD-L1 is a promising target to reverse the immune evasion of gli- oma ...measured PD-L1 expression in 94 patients and found that PD-L1 was a negative ...
13
<p>A meta-analysis of the efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors as treatments for metastatic bladder cancer</p>
... expressing PD-L1, which represents an emerging antitumor ...a PD-1 inhibitor, has been granted full the US Food and Drug Administration (FDA) approval based on its high antitumor activity, ...
11
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
... respective PD-1/PD-L1 inhibitors were designed to screen for the presence of specific PD-1/PD-L1 epi- topes as well as to estimate the percentage of T cells or ...
6
Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
... [27]. PD-L1 expression on tumor cells and immune cells has been shown to enrich for response to anti-PD-1/ L1 in various solid malignancies ...molecules, PD-1 and ...
5
Anti–PD 1/PD L1 therapy of human cancer: past, present, and future
... tumor-associated PD-L1 facilitates apoptosis of activated T cells (17) and also stimulates IL-10 pro- duction in human peripheral blood T cells (4) to mediate immune ...of PD-L1 on immune ...
9
The importance of the PD 1/PD L1 pathway at the maternal fetal interface
... of PD-1 receptor expressed by immune cells at the human MFI [43, ...of PD-1+ CD3+ T cells in the first-trimester decidua compared to the endometrium in non-pregnant controls ...elevated ...
12